Table 4. Recipients with HCC Recurrence^a.

		Basiliximab(n = 78)		Steroid(n = 100)	P-value
Overall recurrence of HCC		35 (44.9)		38 (38.0)	0.355†
Intrahepatic recurrenceb	n = 74	25 (33.8)	n = 94	29 (30.9)	0.686†
Extrahepatic recurrence/transferb	n = 74	23 (31.1)	n = 94	23 (24.5)	0.340†
Transferred locationc
Lung	n = 22	17 (77.3)		13 (56.5)	0.458‡
Bone	n = 22	2 (9.1)		4 (17.4)
Lung+bone	n = 22	2 (9.1)		2 (8.7)
Bone+brain	n = 22	0 (0.0)		1 (4.4)
Lung+bone+brain	n = 22	1 (4.6)		0 (0.0)
Lung+brain	n = 22	0 (0.0)		1 (4.4)
Abdomen	n = 22	0 (0.0)		2 (8.7)
Recurrence of HCC within 1 year		29 (37.2)		28 (28.0)	0.193†
Intrahepatic recurrence within 1 yearb	n = 74	21 (28.4)	n = 94	21 (22.3)	0.370†
Extrahepatic recurrence/transfer within 1 yearb	n = 74	21 (28.4)	n = 94	18 (19.2)	0.160†
Transferred location within 1 yearc
Lung	n = 20	16 (80.0)		9 (50.0)	0.199‡
Bone	n = 20	2 (10.0)		4 (22.2)
Lung+bone	n = 20	1 (5.0)		2 (11.1)
Lung+bone+brain	n = 20	1 (5.0)		0 (0.0)
Lung+brain	n = 20	0 (0.0)		1 (5.6)
Abdomen	n = 20	0 (0.0)		2 (11.1)

Data are presented as number (percentage).

^aThe number of patients for basiliximab and steroid groups are 78 and 100, respectively unless indicated otherwise.

^†Chi-square test;

^‡Fisher’s exact test. NA: non-available.

^bFour subjects in the basiliximab group and 6 subjects in the steroid group had missing data.

^cOne subject in the basiliximab group was missing data.

HCC = hepatocellular carcinoma.